A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumors|Triple Negative Breast Cancer|Chordoma and Alveolar Soft Part Sarcoma
Interventions: DRUG: FAZ053|DRUG: PDR001
Sponsor: Novartis Pharmaceuticals